Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when KYNB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsKyntra Bio receives final $4M from AstraZeneca, completing $220M China sale
Filed June 9, 2026 · Period ending June 2, 2026 · ~1 min read
Key Changes
-
high
Company collected final $4.0 million holdback payment from AstraZeneca on June 2, completing all financial obligations from the August 2025 sale of China operations for total consideration of approximately $220 million.
Item 8.01 verify on EDGAR → -
medium
No indemnity claims were made against the holdback amount, allowing full release of funds. Original sale included $85 million in enterprise value plus approximately $135 million in net cash held in China.
Item 8.01 verify on EDGAR → -
medium
Transaction timeline: $210 million received at August 2025 closing, $6.4 million in November 2025, and final $4.0 million in June 2026, marking complete divestiture of China operations to AstraZeneca.
Item 8.01 verify on EDGAR →
Summary
Kyntra Bio has successfully closed out its $220 million divestiture of China operations to AstraZeneca with receipt of the final $4.0 million holdback payment on June 2, 2026. The holdback was originally set aside to cover potential indemnity claims under the February 2025 share purchase agreement, but with no claims filed, the full amount was released to Kyntra Bio. This completes a transaction that began with an August 2025 closing payment of $210 million, followed by $6.4 million in November 2025.
For retail investors, this filing represents the final chapter of a major strategic shift for Kyntra Bio, which exited its China operations and monetized approximately $135 million in trapped Chinese cash plus $85 million in enterprise value. The clean completion with no indemnity claims suggests a smooth transition and reduces uncertainty about final proceeds. Investors should watch how management deploys this capital—whether toward share buybacks, debt reduction, R&D investment, or other strategic initiatives—as this will shape the company's future direction.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 2, 2026, Kyntra Bio, Inc. (the “Company”) received $4.0 million from AstraZeneca Treasury Limited (“AstraZeneca”). This amount is in full satisfaction of the second and final holdback set forth in the share purchase agreement entered into between the Company and AstraZeneca on February 20, 2025 (the “Share Purchase Agreement”).
The company received the final $4.0 million holdback payment from AstraZeneca on June 2, 2026. This payment was held back to satisfy any potential indemnity claims under the share purchase agreement. Since no indemnity claims were made, the full amount was released to Kyntra Bio.
Added in current filing · verify on EDGAR →
As no indemnity claims were made, the Company has now received the entire $4.0 million holdback, which completes the collection of all owed amounts under the Share Purchase Agreement with AstraZeneca.
Kyntra Bio has now collected all amounts owed under the August 2025 sale of its China operations to AstraZeneca. The total consideration of approximately $220 million has been fully received, including $210 million at closing, $6.4 million in November 2025, and this final $4.0 million payment. This closes out all financial obligations related to the divestiture.
Added in current filing · verify on EDGAR →
On August 29, 2025, the Company closed the sale of its China operations through FibroGen International (Hong Kong) Ltd. to AstraZeneca pursuant to the Share Purchase Agreement for a total consideration of approximately $220 million comprised of $85 million in enterprise value and approximately $135 million in net cash held in China.
The filing provides context on the original transaction: Kyntra Bio sold its China operations to AstraZeneca in August 2025 for approximately $220 million total consideration. This included $85 million in enterprise value and approximately $135 million in net cash that was held in China at the time of sale.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify